Tests nivolumab with chemotherapy for newly diagnosed advanced Hodgkin lymphoma
Tests nivolumab plus AVD chemotherapy in adults with newly diagnosed advanced Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Key facts
- Where
- Moscow, RussiaSee the site
- Phase
- Phase 2
Where in Russia
- P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian FederationMoscow, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Medical Research Radiological Centre of the Ministry of Health of Russia
- Trial code
- NCT06984146
- Record updated
- 26 November 2025
- Original description
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin LymphomaRead full original descriptionShow less
Flat-dose Nivolumab (40 mg) in Combination With Doxorubicin, Vinblastine, and Dacarbazine (AVD) for Newly Diagnosed Advanced Classic Hodgkin Lymphoma
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
Inclusion: Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma; No past history of autoimmune disease; Age > 18 years; Ejection fraction > 50%; ECOG 0-4.
Exclusion: Uncontrolled infection; Organ failure (e.g. creatinine > 2x ULN; ALT or AST > 5x ULN; bilirubin > 2x ULN; hemodynamic instability; respiratory failure > Grade 1); Pregnancy; Inability to sign informed consent.